Susquehanna International Group, LLP Blueprint Medicines Corp Put Options Transaction History

Susquehanna International Group, LLP

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$84.1 - $120.5 $529,830 - $759,150	6,300 Added 1.78%	360,700 $33.4 Million
Q2 2024 Aug 15, 2024	BUY	$85.18 - $108.78 $2.19 Million - $2.8 Million	25,700 Added 7.82%	354,400 $38.2 Million
Q1 2024 May 07, 2024	BUY	$73.17 - $99.79 $7.8 Million - $10.6 Million	106,600 Added 48.0%	328,700 $31.2 Million
Q4 2023 Feb 14, 2024	SELL	$43.96 - $92.84 $2.16 Million - $4.57 Million	-49,200 Reduced 18.13%	222,100 $20.5 Million
Q3 2023 Nov 14, 2023	BUY	$46.9 - $66.0 $1.21 Million - $1.7 Million	25,700 Added 10.46%	271,300 $13.6 Million
Q2 2023 Aug 11, 2023	BUY	$42.2 - $66.37 $1.05 Million - $1.65 Million	24,800 Added 11.23%	245,600 $15.5 Million
Q1 2023 May 16, 2023	BUY	$37.97 - $50.0 $3.49 Million - $4.6 Million	91,900 Added 71.3%	220,800 $9.93 Million
Q4 2022 Feb 14, 2023	BUY	$41.06 - $66.48 $2.52 Million - $4.08 Million	61,400 Added 90.96%	128,900 $5.65 Million
Q3 2022 Nov 14, 2022	BUY	$49.93 - $77.7 $1.55 Million - $2.41 Million	31,000 Added 84.93%	67,500 $4.45 Million

350

60.3M

2.25M

1.18M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.3B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.